N. Murthy

Effects of Citalopram Infusion on the Serotonin Transporter Binding of [11C]DASB in Healthy Controls

P. Cowen, P. Grasby, Z. Bhagwagar, 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Computerized cognitive remediation training for schizophrenia: An open label, multi-site, multinational methodology study

S. Kapur, B. Wexler, P. Maruff, 2012, Schizophrenia Research.

Autistic-like behaviour profile and psychiatric morbidity in Fragile X Syndrome

A. Wijeratne, N. Murthy, S. Payne, 2003, European child & adolescent psychiatry.

A Functional Genetic Variation of the Serotonin (5-HT) Transporter Affects 5-HT1A Receptor Binding in Humans

Sean P David, S. David, P. Grasby, 2005, The Journal of Neuroscience.

5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB.

P. Cowen, P. Grasby, Z. Bhagwagar, 2007, The American journal of psychiatry.

Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain

Marc Laruelle, Barbara J. Sahakian, Eugenii A. Rabiner, 2010, NeuroImage.

5-HT1A receptor density and defensive personality - interaction of neurochemistry, personality and depression explored with [11C]WAY 100635 PET

P. Cowen, A. Lawrence, P. Grasby, 2005 .

Relationship Between Glycine Transporter 1 Inhibition as Measured with Positron Emission Tomography and Changes in Cognitive Performances in Nonhuman Primates

R N Gunn, R E Carson, M Laruelle, 2014, Neuropsychopharmacology.

Human 5-HT Transporter Availability Predicts Amygdala Reactivity In Vivo

M. Alex Dresner, Philip J. Cowen, Sudhakar Selvaraj, 2007, The Journal of Neuroscience.

Brain serotonin transporter binding in former users of MDMA ('ecstasy').

P. Cowen, P. Grasby, Z. Bhagwagar, 2009, The British journal of psychiatry : the journal of mental science.

Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder.

Philip D. Harvey, N. Murthy, Rengyi Xu, 2019, Journal of affective disorders.

Vortioxetine 5, 10, and 20 mg Significantly Reduces the Risk of Relapse Compared With Placebo in Patients With Remitted Major Depressive Disorder: The RESET Study.

M. Thase, N. Murthy, Rengyi Xu, 2022, Journal of affective disorders.